Scienture Holdings, Inc. (SCNX)
Automate Your Wheel Strategy on SCNX
With Tiblio's Option Bot, you can configure your own wheel strategy including SCNX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SCNX
- Rev/Share 0.0156
- Book/Share 9.0362
- PB 0.1151
- Debt/Equity 0.0447
- CurrentRatio 0.7975
- ROIC -0.1433
- MktCap 13641056.0
- FreeCF/Share -1.6302
- PFCF -0.9562
- PE 1.0038
- Debt/Assets 0.0337
- DivYield 1.4423
- ROE 0.1913
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
SCIENTURE Announces Executive Leadership Transition
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
TAMPA, FL, May 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that Suren Ajjarapu, who has served as Chief Executive Officer (CEO) and Chairman of the Board of Directors (BOD), has stepped down from his roles with the Company, with those positions being assumed by the existing, experienced management team of Dr. Shankar Hariharan and Dr. Narasimhan Mani.
Read More
SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
TAMPA, FL, May 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that the U.S. Food and Drug Administration (FDA) has listed U.S. Patent Nos. 11890273 (the ‘273 patent) and 12156869 (the '869 patent), each with an expiration date of October 2041, in its Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) for Arbli™, (losartan …
Read More
About Scienture Holdings, Inc. (SCNX)
- IPO Date 2014-02-06
- Website https://www.trxadehealth.com
- Industry Medical - Healthcare Information Services
- CEO Dr. Shankar Hariharan Ph.D.
- Employees 14